We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J (JNJ) Beats on Q4 Earnings, Misses Sales, Shares Up
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters, with an average positive surprise of 3.12%.
Estimates for 2018 have gone up slightly over the past 7 days.
Currently, JNJ has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on fourth quarter earnings - the company reported EPS of $1.74 while our consensus called for EPS of $1.72.
Revenues Miss: Revenues slightly missed expectations. Johnson & Johnson posted revenues of $20.20 billion, compared to our consensus estimate of $20.22 billion.
Key Statistics: Pharmaceutical segment sales rose 17.6% year over year to $9.7 billion, reflecting 15.5% operational growth and 2.1% positive currency impact as sales rose in both the domestic and international markets
Issued 2018 Outlook: J&J issued a mixed guidance for 2018 wherein the earnings range was above consensus estimate while sales fell slightly short of the same.
J&J expects 2018 adjusted earnings per share in the range of $8.00 - $8.20. The company’s guidance range topped the Zacks Consensus Estimate which stood at $7.86 per share.
The revenue guidance was in the range of $80.6 billion to $81.4 billion. However, the sales guidance fell short of the Zacks Consensus Estimate of $81.55 billion.
Stock Price Impact: Shares rose 1.1% in pre-market trading.
Check back later for our full write up on this JNJ earnings report later!
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
J&J (JNJ) Beats on Q4 Earnings, Misses Sales, Shares Up
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters, with an average positive surprise of 3.12%.
Estimates for 2018 have gone up slightly over the past 7 days.
Currently, JNJ has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on fourth quarter earnings - the company reported EPS of $1.74 while our consensus called for EPS of $1.72.
Revenues Miss: Revenues slightly missed expectations. Johnson & Johnson posted revenues of $20.20 billion, compared to our consensus estimate of $20.22 billion.
Key Statistics: Pharmaceutical segment sales rose 17.6% year over year to $9.7 billion, reflecting 15.5% operational growth and 2.1% positive currency impact as sales rose in both the domestic and international markets
Issued 2018 Outlook: J&J issued a mixed guidance for 2018 wherein the earnings range was above consensus estimate while sales fell slightly short of the same.
J&J expects 2018 adjusted earnings per share in the range of $8.00 - $8.20. The company’s guidance range topped the Zacks Consensus Estimate which stood at $7.86 per share.
The revenue guidance was in the range of $80.6 billion to $81.4 billion. However, the sales guidance fell short of the Zacks Consensus Estimate of $81.55 billion.
Stock Price Impact: Shares rose 1.1% in pre-market trading.
Check back later for our full write up on this JNJ earnings report later!
Johnson & Johnson Price and Consensus
Johnson & Johnson Price and Consensus | Johnson & Johnson Quote
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >